

# Genentech Early Development Pipeline

## Phase I (12 NMEs)

### ONCOLOGY

#### **ABT-263/Bcl-2 (RG7423)**

- Solid tumors and hematologic malignancies

#### **Anti-EGFL7 (RG7414)**

- Solid tumors

#### **Anti-NRP1 (RG7347)**

- Solid tumors

#### **Dulanermin (RG3639)**

- Colorectal cancer

#### **MEK Inhibitor/GDC-0973 (RG7420)**

- Solid tumors

#### **PI3 Kinase Inhibitor/GDC-0941 (RG7321)**

- Metastatic breast cancer
- Metastatic non-small cell lung cancer

#### **PI3 Kinase Inhibitor/GDC-0980 (RG7422)**

- Solid tumors and non-Hodgkin's lymphoma

### IMMUNOLOGY

#### **Anti-LT $\alpha$ (RG7416)**

- Rheumatoid arthritis

#### **rhuMAb- $\beta$ 7 (RG7413)**

- Ulcerative colitis

### TISSUE GROWTH & REPAIR

#### **Anti-oxLDL (RG7418)**

- Secondary prevention of cardiovascular events

#### **BHT-3021 (RG7426)**

- Type 1 diabetes

### NEUROSCIENCE

#### **Anti-A $\beta$ (RG7412)**

- Alzheimer's disease

### OPHTHALMOLOGY

#### **Anti-Factor D (RG7417)**

- Geographic atrophy associated with age-related macular degeneration

## Phase II (4 NMEs)

### ONCOLOGY

#### **ABT-263/Bcl-2 (RG7423)**

- Relapsed chronic lymphocytic leukemia
- Relapsed lymphoid malignancies
- Small cell lung cancer

#### **MetMAB (RG3638)**

- 2<sup>nd</sup>- and 3<sup>rd</sup>-line metastatic non-small cell lung cancer

### IMMUNOLOGY

#### **Lebrikizumab (RG3637)**

- Asthma

#### **Rontalizumab (RG7415)**

- Systemic lupus erythematosus